HK Stock Market Move | 361 Degrees (01361) rose by over 4% again, reaching a new all-time high in stock price. It is expected that e-commerce and superstores will continue to be the main drivers of growth.
361 Degrees (01361) rose by more than 4% again, reaching a historical high in stock price, with a cumulative drop of over 20% after its performance. As of the time of writing, it rose by 3.58% to HKD 6.66, with a turnover of HKD 54.86 million.
361 DEGREES (01361) rose by over 4%, reaching a historical high in stock price, with a cumulative decline of over 20% after performance. As of the time of writing, it increased by 3.58% to HK$6.66, with a turnover of 54.8686 million Hong Kong dollars.
In terms of news, 361 DEGREES previously released its annual performance, with a group income of 11.146 billion renminbi, a year-on-year increase of 10.64%; net profit attributable to shareholders was 1.309 billion renminbi, a year-on-year increase of 13.95%. The board of directors recommended a dividend of HK$0.113 per share for the end period of the reviewed year, with a full-year dividend payout ratio of 45.0%.
Changjiang released a research report stating that in the short term, the high growth of e-commerce and the expansion of super brand stores are expected to be the main drivers of growth. Short-term optimization of advertising expenses and cash flow improvement also indicate that the company is in a good position. In the medium to long term, the company's overseas expansion efforts are showing results, ONEWAY outdoor high-end brand is making strong efforts, and there is potential to become the second driver of growth in the future. The bank believes that the company is currently in a phase of stable performance realization, improvement in cash flow, and not expensive valuation, and gives a "buy" rating.
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


